First Disclosure of Anti-Fibrotic Effects in Kidney of NUAK1 Inhibitor Preclinical Candidate Group

Oscotec announced on March 23 that it will present results from proof-of-concept (PoC) studies in animal models for its NUAK1 inhibitor preclinical candidate group, part of the "OCT-648" project, at the World Congress of Nephrology (WCN) to be held in Yokohama, Japan, starting on March 28.


Oscotec to Present 'OCT-648' Research Results at the World Congress of Nephrology View original image

The OCT-648 project, which focuses on developing therapeutics to inhibit renal fibrosis, targets NUAK1 and is based on a mechanism that suppresses the early fibrotic response by blocking nuclear signaling of fibrosis-activating genes. This differentiated approach aims at directly targeting the progression of fibrosis—a common pathological mechanism in kidney disease—by indirectly modulating the YAP/TAZ signaling pathway, a key transcriptional regulatory pathway in renal fibrosis, through NUAK1 inhibition.


According to histopathological analyses in preclinical renal fibrosis models, the NUAK1 inhibitor demonstrated consistent anti-fibrotic effects, including reduced fibrotic area, inhibition of fibroblast activation, and decreased collagen accumulation. The company explained that higher dosing led to a proportional reduction in fibrosis markers and showed stable drug effects. Oscotec expects that NUAK1 inhibitors could be developed into therapeutics broadly applicable to various causes of chronic kidney disease.


At this year's WCN, Oscotec will present a poster focused on preclinical data for the NUAK1 inhibitor candidate group targeting renal fibrosis. Key researchers, including Hyesuk Shim, who joined the company last year as Executive Director, will attend the event to present the preclinical results and introduce the differentiated development strategy for the NUAK1 inhibitor. The company also plans to actively seek technology transfer opportunities by networking with global partners.


Tae Young Yoon, CEO of Oscotec, stated, "Existing chronic renal failure treatments have limitations in preventing the loss of kidney function resulting from the progression of fibrosis. Recently, there has been a growing need for new therapeutics that directly inhibit renal fibrosis." He continued, "Oscotec's NUAK1 inhibitor has a mechanistic advantage in that it can be applied to all renal failure patients by blocking the early pathway of fibrosis, and the candidate compound has secured safety suitable for chronic disease therapeutics due to its excellent NUAK1 selectivity."


Young Shin Kwak, Head of Research at Oscotec, said, "For the OCT-648 project, we plan to finalize the candidate compound within the first half of this year, begin preclinical development in the second half, and aim to enter clinical trials in 2027."



Meanwhile, Oscotec is a drug development company established in 1998 and is the original developer of "Leclaza (ingredient: Lazertinib)", a non-small cell lung cancer treatment licensed to Yuhan Corporation. In December last year, Oscotec licensed out "ADEL-Y01," an Alzheimer's disease drug candidate targeting tau protein, which was co-developed with Adel, to the global healthcare company Sanofi.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing